Rubicon Research Ltd

Rubicon Research Ltd has filed its Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its Initial Public Offering (IPO). The report, issued by India Ratings and Research Private Limited, confirms no deviation from the stated objects of the issue. The utilization of IPO proceeds was reviewed and taken on record by the Audit Committee and Board of Directors on August 14, 2026. The IPO, which occurred from October 9-13, 2025, raised INR 5,000 Million through a fresh issue of equity shares, with an additional INR 8,775.00 Mn from an offer for sale, totaling INR 13,775.00 Mn.

Rubicon Research Ltd announced key leadership changes following its Board Meeting on August 14, 2026. Mr. Rohit Saraogi has been appointed as the Chief Financial Officer (CFO) and Senior Management Personnel, effective August 14, 2026. He will also assume the role of Key Managerial Personnel (KMP). Mr. Nitin Jajodia, the current CFO, will transition to the role of Chief Commercial Officer (CCO). Additionally, the Board approved the re-appointment and extension of Mr. Venkat Changavalli's term as Chairman, effective September 18, 2026, until June 10, 2027. These changes are positioned as strategic steps for the company's future growth.

Rubicon Research's consolidated print for the quarter ended June 30, 2026 came in well ahead of the revenue range flagged in our pre-result preview (₹350–370 Cr) at ₹534.3 Cr, though that preview range was already below the prior quarter's own ₹513.9 Cr base, so the comparison is of limited use. On margins, the preview's 32–35% EBITDA-margin expectation was not met — actual consolidated EBITDA margin works out to roughly 25.2% (standalone ~29.8%). We could not find a formal analyst consensus for this print (WebSearch turned up none, consistent with our own preview's note that coverage is thin and the stock trades on the growth/capital-deployment narrative rather than consensus earnings forecasts), so vsStreet is unknown. Against management's own guidance, the quarter is a clear beat: at the Q4FY26 call management reiterated an EBITDA margin band of 22–23% for coming quarters, factoring in ESOP costs, Arinna-related expenses and Pithampur ramp-up. Actual consolidated margin of ~25.2% (standalone ~29.8%) sits above that band. Consolidated NPM also expanded to 15.7%, from 14.9% in Q4FY26 and 12.3% a year ago, so the margin trend is expanding on both a sequential and annual basis. The mechanics behind the print are worth separating from the headline growth. Consolidated revenue (+51.6% YoY, +4.0% QoQ) and PAT (+95.8% YoY, +10.4% QoQ) both grew strongly, but consolidated PBT (₹110.4 Cr) was essentially flat versus standalone PBT (₹110.7 Cr) even though consolidated revenue is 25% higher — the four subsidiaries not independently reviewed by the parent's auditors (which include Arinna, consolidated only from April 30, 2026) contributed a combined ₹14.2 Cr net loss for the quarter, an integration drag that shows up below the revenue line. Consolidated PAT nonetheless finished above standalone PAT because of a lower group effective tax rate (23.2% vs 25.5% standalone) rather than because the new subsidiaries were profit-accretive this quarter. Corporate activity this quarter lines up with the pre-result thesis: the ₹175.9 Cr, 85%-stake Arinna Lifesciences acquisition completed April 30, 2026 and is now consolidated (with the caveat above); the board approved a Kia Health Tech amalgamation scheme on July 20, 2026 (filed with the RoC on August 3, 2026, not yet effective, so no P&L impact this quarter); and of the ₹471.3 Cr net IPO proceeds, ₹80.6 Cr remains unutilised as of June 30, 2026, with the deployment timeline extended to March 31, 2027. Post quarter-end, subsidiary AdvaGen Holdings acquired a US manufacturing facility in East Brunswick, New Jersey for USD 2.9 million, extending the US CDMO footprint flagged in the preview. No management press release was available in the extraction context to cross-check against their own framing of the quarter, so the numbers above are the primary signal on execution this period.

Rubicon Research Ltd has issued a corrigendum to its Integrated Annual Report for the financial year 2025-26. This follows an earlier intimation regarding the Notice of the 27th Annual General Meeting. The corrections address minor typographical errors, including specific figures in the Management Discussion & Analysis section (pages 76-78) and adjustments to Shareholding Pattern categories to align with the quarter ended March 31, 2026. The percentage stake acquired in Arinna Lifesciences Limited has also been updated. Importantly, there are no changes to the Notice of the 27th Annual General Meeting. The revised Integrated Annual Report is attached and available on the company's website.

Rubicon Research Ltd. has announced its 27th Annual General Meeting (AGM) scheduled for August 26, 2026, at 1:00 PM IST, to be conducted via Video Conferencing. The company has also released its Integrated Annual Report for the financial year 2025-26. The report and AGM notice are being disseminated via email to eligible members and a web-link will be provided to those without registered email addresses. Key dates for e-voting have been set, with the cut-off on August 19, 2026, and remote e-voting commencing August 22 and concluding August 25, 2026. The results of the e-voting will be announced within two working days post-AGM. The annual report highlights the company's IP-led specialty pharmaceutical approach, focusing on innovation, quality, and care to address unmet medical needs.

Rubicon Research Ltd has announced its schedule for an Earnings Conference Call to discuss its financial performance for the first quarter of the fiscal year 2027 (ended June 30, 2026). The call is set to take place on Friday, August 14, 2026. Senior management, including the CEO, CFO, and SVP of Corporate Development & Strategy, will represent the company. The call will also feature Tushar Manudhane from Motilal Oswal Financial Services as the Call Leader. Dial-in details for various regions, including India, Singapore, Hong Kong, UK, and USA, have been provided.

Rubicon Research Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda item is to consider and approve the un-audited standalone and consolidated financial results for the first quarter ended June 30, 2026. In compliance with SEBI regulations and the company's insider trading code, the trading window for company shares has been closed from July 1, 2026, and will reopen 48 hours after the financial results are announced.

Rubicon Research Ltd. has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, which also forms part of the Integrated Annual Report for FY2025-26, is available on the company's website. It details the company's corporate information, business activities focused entirely on pharmaceutical formulations, and operational presence including 3 national plants and 7 international offices. Exports account for 98.44% of total turnover. The report also provides employee demographics and details on female representation on the Board and among Key Management Personnel.

Rubicon Research Ltd has announced its 27th Annual General Meeting (AGM) scheduled for August 26, 2026, at 1:00 PM IST via Video Conferencing. The company has also released its Integrated Annual Report for the financial year 2025-26. The notice and report are being sent via email to eligible members, with a web link provided for others. Key dates include the cut-off for e-voting on August 19, 2026, and the commencement and end of remote e-voting on August 22 and August 25, 2026, respectively. Results of e-voting will be announced within two working days post-AGM.

Rubicon Research Ltd has issued a communication regarding the tax deduction at source (TDS) on the final dividend for FY 2025-26. The Board has recommended a dividend of ₹1.50 per equity share, subject to shareholder approval at the 27th AGM on August 26, 2026. The communication clarifies the applicability of TDS as per the Income Tax Act, 2025, and outlines the process for shareholders to ensure correct tax deduction. Shareholders are advised to update their PAN, residential status, and other KYC details with their Depository Participants before the Record Date of August 7, 2026. It details TDS rates and exemption conditions for resident individuals and non-individual resident shareholders, including the process for submitting Form 121 electronically.